Helen Mann

Publications by Year

Research Areas

Lung Cancer Research Studies, Neuroendocrine Tumor Research Advances, Peptidase Inhibition and Analysis, Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies

Most-Cited Works

• → Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer(2016)3,266 cited
• → Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study(2016)636 cited
• → Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer(2023)601 cited
• → Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component(2017)565 cited
• → Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer(2017)526 cited
• Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer(2017)
• → TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer(2020)433 cited
• → Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study(2020)360 cited
• → Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy(2015)298 cited
• → Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN(2022)297 cited